Dr. Jesus Beltran has nearly two decades of international experience in biomedical research, with a career spanning bioengineering, gene regulation, and cellular reprogramming.

He earned a degree in biotechnology and a master in biomedical research before completing his PhD at the University of Valencia, where he graduated with the highest honors and received the outstanding dissertation award. Following his PhD, Dr. Beltran joined the University of California, San Diego, as a postdoctoral researcher in the laboratory of Professor Dan Kaufman. There, he pioneered an in vivo cell editing platform to reprogram immune cells directly inside the human body—technology that has since been licensed to ONO Pharmaceuticals and is now advancing toward clinical trials for the treatment of solid tumors. Dr. Beltran then moved to the laboratory of Professor Darrell Irvine, an HHMI investigator and bioengineering professor at MIT and Harvard. There, he worked on developing RNA engineering technologies for precise spatial and temporal control of therapeutic cargo.

Dr. Beltran has been recognized by leading national and international institutions, including the NIH, EMBO, and MIT. He is the co-founder and CSO of DNAmic Biosystems, where he leads the development of next-generation platforms for cell editing and advanced therapies. Throughout his career, he has published 26 scientific articles and four book chapters, accumulating more than 800 citations, and is the inventor of multiple patents.